In a phase-II trial, Lung-MAP substudy S1800A, the combination of ramucirumab with pembrolizumab vs. SOC was tested in advanced NSCLC patients that previously received PD-1 or PD-L1 therapy and progressed after at least 84 days. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.